Spots Global Cancer Trial Database for Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma
Official Title: An Open-label, Phase II Trial of Patupilone (EPO906) as Monotherapy to Evaluate Activity of Patupilone in Patients With Advanced Unresectable and/or Metastatic Hepatocellular Carcinoma (HCC)
Study ID: NCT00273312
Conditions
Interventions
Study Description
Brief Summary: This study will evaluate the safety, efficacy, and activity of patupilone in patients with advanced unresectable and/or metastatic hepatocellular carcinoma based on tumor response using modified RECIST criteria.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Novartis Investigative Site, San Francisco, California, United States
Novartis Investigative Site, Hong Kong, Shatin, NT, Hong Kong
Novartis Investigative Site, Hong Kong, , Hong Kong
Novartis Investigative Site, Seoul, Korea, Korea, Republic of
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Taipei, Taiwan ROC, Taiwan
Novartis Investigative Site, Tai Chung Municipality, , Taiwan
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
